[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 56 of about 56

Advertisement
4. Sharp JA, Mailer SL, Thomson PC, Lefèvre C, Nicholas KR: Identification and transcript analysis of a novel wallaby (Macropus eugenii) basal-like breast cancer cell line. Mol Cancer; 2008;7:1
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and transcript analysis of a novel wallaby (Macropus eugenii) basal-like breast cancer cell line.
  • Murine, feline and canine mammary tumor cell lines have been studied for several decades and have been shown to have numerous aspects in common with human breast cancer.
  • The primary tumor was 1.5 cm3 and although large, did not appear to invade the stroma and lacked vimentin expression.
  • The WalBC cell line was cultured from the primary tumor and passaged for 22 months.
  • WalBC cells displayed an epithelial morphology when grown on plastic, were not EGF responsive, stained strongly for cyto-keratin and negatively for vimentin.
  • WalBC cells exhibited expression of known markers of basal invasive human breast cancers as well as increased KRT17, KRT 14 and KRT 19, DSP, s100A4, NDRG-1, ANXA1, TK1 and AQP3 gene expression and decreased gene expression of TIMP3, VIM and TAGLN.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Macropodidae / genetics. Mammary Neoplasms, Animal / genetics. Mammary Neoplasms, Animal / pathology. RNA, Neoplasm / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Down-Regulation. Epithelial Cells / cytology. Female. Gene Expression Profiling. Genes, Neoplasm. Humans. Neoplasm Invasiveness. RNA, Messenger / genetics. RNA, Messenger / metabolism. Up-Regulation


5. Kuroda N, Fujishima N, Inoue K, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH: Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas. Med Mol Morphol; 2008 Jun;41(2):117-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas.
  • Some investigators have previously suggested that basal-like carcinoma may consist of components of invasive ductal carcinoma, not otherwise specified, metaplastic carcinoma, and medullary carcinoma.
  • We report here two cases of breast carcinoma showing basal cell/myoepithelial differentiation.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Neoplasm Metastasis / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592167.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


6. Barboza CA, Pereira Pinto L, Freitas Rde A, Costa Ade L, Souza LB: Proliferating cell nuclear antigen (PCNA) and p53 protein expression in ameloblastoma and adenomatoid odontogenic tumor. Braz Dent J; 2005;16(1):56-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferating cell nuclear antigen (PCNA) and p53 protein expression in ameloblastoma and adenomatoid odontogenic tumor.
  • In this study, proliferating cell nuclear antigen (PCNA) and p53 protein expressions were analyzed in 16 cases of ameloblastoma and 8 cases of adenomatoid odontogenic tumor (AOT).
  • In some specimens, more than one histologic subtype was identified in the same lesion, and each tumor was categorized according to the predominant cell pattern.
  • The odontogenic tumors were grouped as follows: follicular ameloblastoma (n=7), plexiform ameloblastoma (n=4), acanthomatous + follicular ameloblastoma (n=3), basal cell ameloblastoma (n=2), adenomatoid odontogenic tumor (n=8).
  • [MeSH-major] Ameloblastoma / metabolism. Odontogenic Tumors / metabolism. Proliferating Cell Nuclear Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Analysis of Variance. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness. Statistics, Nonparametric

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16113935.001).
  • [ISSN] 0103-6440
  • [Journal-full-title] Brazilian dental journal
  • [ISO-abbreviation] Braz Dent J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


7. Bohn AA, Wills T, Caplazi P: Basal cell tumor or cutaneous basilar epithelial neoplasm? Rethinking the cytologic diagnosis of basal cell tumors. Vet Clin Pathol; 2006 Dec;35(4):449-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell tumor or cutaneous basilar epithelial neoplasm? Rethinking the cytologic diagnosis of basal cell tumors.
  • The cytologic interpretation was malignant neoplasia with histiocytic inflammation.
  • Differentials included a carcinoma or, given the melanin pigment and variable morphology of the cells, possibly malignant melanoma.
  • Histologically, the tumor was diagnosed as a basal cell epithelioma.
  • Neoplasms that once were lumped into the broad histologic diagnosis of basal cell tumors have since been split into distinct entities, dependent on evidence of differentiation into epidermis, trichofollicular epithelium, or sweat or sebaceous glands.
  • Although histologic reclassification has resulted in removal of most of these entities from the original basal cell tumor category, a cytologic diagnosis of basal cell tumor continues to be used to represent the large, heterogeneous group of epidermal, trichofollicular, and adnexal skin tumors with basal cell characteristics.
  • The case in this report demonstrates the heterogeneity of neoplasms that may be diagnosed cytologically as basal cell tumors and supports the need for cytologic criteria and nomenclature that better reflect potential variation in tissue differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123253.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Slanchev K, Carney TJ, Stemmler MP, Koschorz B, Amsterdam A, Schwarz H, Hammerschmidt M: The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin development. PLoS Genet; 2009 Jul;5(7):e1000563
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epithelial cell adhesion molecule EpCAM is required for epithelial morphogenesis and integrity during zebrafish epiboly and skin development.
  • The aberrant expression of the transmembrane protein EpCAM is associated with tumor progression, affecting different cellular processes such as cell-cell adhesion, migration, proliferation, differentiation, signaling, and invasion.
  • Maternal-zygotic mutants display compromised basal protrusive activity and epithelial morphogenesis in cells of the enveloping layer (EVL) during epiboly.
  • In partial redundancy with E-cadherin (Ecad), EpCAM made by EVL cells is further required for cell-cell adhesion within the EVL and, possibly, for proper attachment of underlying deep cells to the inner surface of the EVL, thereby also affecting deep cell epiboly movements.
  • During later development, EpCAM per se becomes indispensable for epithelial integrity within the periderm of the skin, secondarily leading to disrupted morphology of the underlying basal epidermis and moderate hyper-proliferation of skin cells.
  • On the molecular level, EVL cells of epcam mutant embryos display reduced levels of membranous Ecad, accompanied by an enrichment of tight junction proteins and a basal extension of apical junction complexes (AJCs).
  • In addition, EpCAM is required for the interaction of the epithelia with underlying cell layers.
  • [MeSH-major] Antigens, Neoplasm / physiology. Cell Adhesion Molecules / physiology. Epithelium / growth & development. Membrane Glycoproteins / physiology. Morphogenesis. Skin / growth & development. Zebrafish Proteins / physiology
  • [MeSH-minor] Animals. Cadherins / physiology. Cell Adhesion. Embryo, Nonmammalian. Epithelial Cell Adhesion Molecule. Zebrafish

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ZFIN: Data: Gene Expression .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1990 Apr;108(4):581-94 [2387237.001]
  • [Cites] Dev Comp Immunol. 2008;32(1):36-49 [17553562.001]
  • [Cites] J Cell Sci. 1999 Dec;112 ( Pt 23):4415-23 [10564659.001]
  • [Cites] Development. 2005 Mar;132(6):1187-98 [15703282.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Dev Cell. 2005 Jan;8(1):97-108 [15621533.001]
  • [Cites] Exp Cell Res. 2005 Oct 1;309(2):345-57 [16054130.001]
  • [Cites] Development. 2008 Nov;135(22):3625-41 [18952908.001]
  • [Cites] Mol Cell Biol. 1993 Mar;13(3):1507-15 [8382772.001]
  • [Cites] Histochemistry. 1987;87(5):491-8 [3323146.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):315-21 [17622246.001]
  • [Cites] Development. 2006 Jul;133(14):2671-81 [16794032.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Development. 1999 Sep;126(17):3735-45 [10433904.001]
  • [Cites] Cancer Lett. 2005 Jul 8;225(1):151-7 [15922867.001]
  • [Cites] Exp Cell Res. 1999 Jan 10;246(1):108-21 [9882520.001]
  • [Cites] Results Probl Cell Differ. 2002;40:117-35 [12353473.001]
  • [Cites] Hum Mol Genet. 2007 Nov 1;16(21):2583-90 [17673451.001]
  • [Cites] Front Biosci. 2008;13:3096-100 [17981779.001]
  • [Cites] Development. 2005 Jul;132(14):3255-65 [15983403.001]
  • [Cites] Cytopathology. 2005 Aug;16(4):193-8 [16048505.001]
  • [Cites] J Mol Med (Berl). 1999 Oct;77(10):699-712 [10606205.001]
  • [Cites] Acta Anat (Basel). 1988;133(4):325-36 [3227794.001]
  • [Cites] Hepatol Res. 2006 Jan;34(1):50-6 [16364680.001]
  • [Cites] Nat Genet. 2000 Oct;26(2):216-20 [11017081.001]
  • [Cites] Dev Biol. 2008 Mar 1;315(1):1-17 [18215655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Mar;76(3):1438-42 [286328.001]
  • [Cites] Dev Biol. 2008 Apr 1;316(1):36-49 [18275946.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2713-24 [10541557.001]
  • [Cites] Dev Cell. 2002 May;2(5):617-27 [12015969.001]
  • [Cites] J Pathol. 1999 Jun;188(2):201-6 [10398165.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Development. 2005 Mar;132(5):1105-16 [15689372.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1788-94 [9586892.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5818-24 [15313925.001]
  • [Cites] J Cell Biol. 1997 Dec 1;139(5):1337-48 [9382878.001]
  • [Cites] Curr Biol. 2007 Mar 20;17(6):475-87 [17331724.001]
  • [Cites] Front Biosci. 2008;13:5050-5 [18508569.001]
  • [Cites] Mech Dev. 2005 Jul;122(7-8):949-58 [15925497.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2139-48 [14633587.001]
  • [Cites] Dev Dyn. 2005 Feb;232(2):359-68 [15614774.001]
  • [Cites] Dev Cell. 2002 May;2(5):607-16 [12015968.001]
  • [Cites] Transgenic Res. 2008 Apr;17(2):229-38 [17940847.001]
  • [Cites] Nat Cell Biol. 2009 Feb;11(2):162-71 [19136966.001]
  • [Cites] Curr Opin Cell Biol. 2007 Oct;19(5):508-14 [17935963.001]
  • [Cites] Anat Embryol (Berl). 1979 Oct;157(2):121-32 [517761.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):962-7 [9927676.001]
  • [Cites] J Pathol. 2008 Oct;216(2):201-8 [18702175.001]
  • [Cites] Mol Cell Biochem. 2007 Aug;302(1-2):19-26 [17646933.001]
  • [Cites] Gene Expr Patterns. 2007 Aug;7(7):767-76 [17632043.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1519-34 [9508783.001]
  • [Cites] Development. 1996 Dec;123:95-102 [9007232.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):12792-7 [15256591.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):624-8 [17122775.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):386-95 [17600130.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2883-91 [3552208.001]
  • [Cites] Exp Cell Res. 2004 Jul 15;297(2):329-47 [15212938.001]
  • [Cites] Dev Dyn. 2002 Mar;223(2):204-15 [11836785.001]
  • [Cites] Int J Dev Biol. 2004;48(2-3):217-31 [15272388.001]
  • [Cites] Somatic Cell Genet. 1979 Nov;5(6):957-71 [94699.001]
  • [Cites] Histochem J. 1998 Oct;30(10):723-9 [9873999.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):437-46 [8163559.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1035-8 [10508613.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):417-23 [17211480.001]
  • [Cites] Mech Dev. 2005 Jun;122(6):747-63 [15905076.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):143; author reply 143 [19132011.001]
  • [Cites] Mech Dev. 2001 Jul;105(1-2):69-77 [11429283.001]
  • [Cites] J Invest Dermatol. 1987 Nov;89(5):500-6 [3668293.001]
  • [Cites] J Cell Sci. 2007 Oct 1;120(Pt 19):3372-83 [17881499.001]
  • [Cites] PLoS Biol. 2009 Jan 6;7(1):e9 [19127979.001]
  • [Cites] Oncogene. 1999 Apr 8;18(14):2323-34 [10327052.001]
  • [Cites] J Cell Sci. 2004 May 15;117(Pt 12):2435-47 [15159449.001]
  • [Cites] Genes Dev. 2007 Jul 15;21(14):1817-31 [17639085.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Apr;87(7):2755-9 [2108441.001]
  • [Cites] Dev Dyn. 2008 Apr;237(4):1153-64 [18351656.001]
  • [Cites] Cell. 2005 Dec 2;123(5):889-901 [16325582.001]
  • [Cites] Exp Cell Res. 2003 Apr 15;285(1):50-8 [12681286.001]
  • [Cites] Development. 1993 Oct;119(2):447-56 [8287796.001]
  • [Cites] J Biol Chem. 1993 Nov 15;268(32):24232-41 [7693697.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5748-58 [15195135.001]
  • [Cites] Dev Dyn. 2006 Jun;235(6):1578-88 [16552761.001]
  • [Cites] J Cell Sci. 2008 Jul 15;121(Pt 14):2406-14 [18577576.001]
  • [Cites] Development. 1990 Apr;108(4):569-80 [2387236.001]
  • [Cites] Curr Opin Genet Dev. 2006 Aug;16(4):433-41 [16797963.001]
  • [Cites] Development. 2007 Oct;134(19):3461-71 [17728346.001]
  • [Cites] Dev Cell. 2005 Oct;9(4):555-64 [16198297.001]
  • (PMID = 19609345.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / R01 RR012589; United States / NIGMS NIH HHS / GM / 1 R01-GM63904; United States / NIGMS NIH HHS / GM / R01 GM063904-01; United States / NIGMS NIH HHS / GM / R01 GM063904; United States / NCRR NIH HHS / RR / 2 R01-RR012589-6
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Epithelial Cell Adhesion Molecule; 0 / Membrane Glycoproteins; 0 / Tacstd protein, zebrafish; 0 / Zebrafish Proteins
  • [Other-IDs] NLM/ PMC2700972
  •  go-up   go-down


9. Ali TZ, Epstein JI: Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am J Surg Pathol; 2007 May;31(5):697-705
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases.
  • We studied 29 cases of basal cell carcinoma of the prostate including what others call adenoid cystic carcinoma of the prostate.
  • Other patterns included: basal cell hyperplasialike in 9 cases (32%); small tubules occasionally lined by a hyaline rim in 9 cases (32%), with 4 of these cases also demonstrating intermingling cords of cells; and large solid nests in 8 cases (28.5%), 5 of which had central necrosis.
  • Infiltration around benign glands was seen in 10 (36%) cases, with predominantly small nests and AC-P.
  • Perineural and vascular invasion was seen in 2 basal cell carcinomas with large basaloid nests.
  • Basal cell markers (HMWCK, p63) either:.
  • Seven patients had RP with: 5/7 showing extraprostatic extension with 1/5 also showing seminal vesicle involvement and 2/5 also with a positive margin; 1/7 having organ confined disease; and 1/7 showing no residual disease.
  • Of 19 (77%) cases, 14 had no evidence of disease after 1 to 19 (mean 5.8) years.
  • Basal cell carcinomas are rare tumors with a broad morphologic spectrum.
  • The most common morphology among those with an aggressive behavior is large solid nests more often with central necrosis, high Ki67%, and less staining with basal cell markers.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biopsy, Needle. Combined Modality Therapy. Humans. Male. Middle Aged. Mitosis. Neoplasm Recurrence, Local. Retrospective Studies. Transurethral Resection of Prostate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460452.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


10. Lau SK, Romansky SG, Weiss LM: Sustentaculoma: report of a case of a distinctive neoplasm of the adrenal medulla. Am J Surg Pathol; 2006 Feb;30(2):268-73
MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustentaculoma: report of a case of a distinctive neoplasm of the adrenal medulla.
  • A case of a morphologically distinctive tumor of the adrenal medulla occurring in a 54-year-old woman is described.
  • On microscopic examination, the tumor was well circumscribed and characterized by the presence of ill-defined, irregular nests of spindle cells with oval to elongated nuclei, tiny nucleoli, and abundant eosinophilic cytoplasm.
  • The tumor was associated with a moderate infiltrate of lymphocytes and plasma cells with occasional lymphoid follicles.
  • Immunohistochemical studies demonstrated the tumor cells to be strongly reactive for vimentin, S-100 protein, and CD56, and nonreactive for glial fibrillary acidic protein, chromogranin, synaptophysin, melanoma-associated antigens, and dendritic cell markers.
  • Ultrastructural examination showed elongated cells with interdigitating cytoplasmic processes devoid of a basal lamina.
  • The morphology, immunophenotype, and ultrastructure of this unique neoplasm suggest derivation from sustentacular cells of the adrenal medulla.
  • We propose the designation "sustentaculoma" for this hitherto undescribed neoplasm of the adrenal gland.
  • [MeSH-major] Adrenal Gland Diseases / metabolism. Adrenal Gland Diseases / pathology. Adrenal Medulla / metabolism. Adrenal Medulla / pathology. Biomarkers, Tumor / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434904.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


11. Godde NJ, Galea RC, Elsum IA, Humbert PO: Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions. J Mammary Gland Biol Neoplasia; 2010 Jun;15(2):149-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions.
  • Such epithelial-mesenchymal plasticity requires complex cellular reprogramming to orchestrate a change in cell shape to an alternate morphology more conducive to migration.
  • During this process, epithelial characteristics, including apical-basal polarity and specialised cell-cell junctions are lost and mesenchymal properties, such as a front-rear polarity associated with weak cell-cell contacts, increased motility, resistance to apoptosis and invasiveness are gained.
  • The ability of epithelial cells to undergo transitions through cell polarity states is a central feature of epithelial-mesenchymal plasticity.
  • These cell polarity states comprise a set of distinct asymmetric distributions of cellular constituents that are fashioned to allow specialized cellular functions, such as the regulated homeostasis of molecules across epithelial barriers, cell migration or cell diversification via asymmetric cell divisions.
  • Each polarity state is engineered using a molecular toolbox that is highly conserved between organisms and cell types which can direct the initiation, establishment and continued maintenance of each asymmetry.
  • Here we discuss how EMT pathways target cell polarity mediators, and how this EMT-dependent change in polarity states impact on the various stages of breast cancer.
  • Emerging evidence places cell polarity at the interface of proliferation and morphology control and as such the changing dynamics within polarity networks play a critical role in normal mammary gland development and breast cancer progression.
  • [MeSH-major] Breast Neoplasms / physiopathology. Cell Polarity / physiology. Cell Transdifferentiation. Epithelial Cells / physiology. Mammary Glands, Human / physiology. Mammary Glands, Human / physiopathology. Mesenchymal Stromal Cells / physiology
  • [MeSH-minor] Animals. Cell Dedifferentiation. Cell Differentiation. Disease Progression. Female. Homeostasis. Humans. Intercellular Junctions. Mammary Glands, Animal / cytology. Mammary Glands, Animal / physiology. Mammary Glands, Animal / physiopathology. Mammary Neoplasms, Experimental / pathology. Mammary Neoplasms, Experimental / physiopathology. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20461450.001).
  • [ISSN] 1573-7039
  • [Journal-full-title] Journal of mammary gland biology and neoplasia
  • [ISO-abbreviation] J Mammary Gland Biol Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 238
  •  go-up   go-down


12. Marci V, Volante M, Cappia S, Righi L, Novello C, Scagliotti GV, Brambilla E, Papotti M: Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma. Virchows Arch; 2007 Sep;451(3):729-36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 2004 WHO classification of lung tumours recognised basaloid carcinoma as a variant of squamous and large cell carcinoma.
  • An 82-year-old man underwent pulmonary lobectomy for a 2.8 cm tumour.
  • The patient is disease-free 13 months after diagnosis.
  • The solid component was an organoid proliferation of basaloid-type cells, as in cutaneous basal cell carcinoma.
  • This tumour is unique in several respects:.
  • (1) The solid areas resemble a conventional basaloid carcinoma, except for the presence of small mucin-containing spaces. (2) The mucinous adenocarcinoma areas contain two layers of columnar and basaloid cells. (3) Both components are neoplastic based on cell morphology, invasive properties and phenotypic profile.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell. Humans. Keratins / analysis. Male. Mucins / analysis. Neoplasm Invasiveness. Phenotype. World Health Organization

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618455.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


13. Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, Geradts J: Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res; 2005 Jun 15;11(12):4357-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
  • We have now done validation experiments on a group of three cell membrane components that had previously not been implicated in breast cancer.
  • We also studied the expression of three other cell membrane proteins known to play a role in mammary neoplasia.
  • We also studied fresh pellets and paraffin-embedded cell buttons of nine human breast cell lines.
  • The NET-6 gene was transfected into a low-expressing cell line, and the effect on cellular morphology, growth, and invasion in vitro was recorded.
  • RESULTS: Celsr2 was down-regulated in one cell line and in 7% of breast cancers.
  • E-cadherin, Kai1, and CD9 were down-regulated in 35%, 76%, and 79% of tumors, respectively, confirming the important role of these markers in human mammary neoplasia.
  • In breast cancer cell lines and tissues, TROP-2 was generally expressed at low levels, although a few specimens showed relative overexpression.
  • In addition, NET-6 was markedly down-regulated in estrogen receptor-negative breast cancers, and expression was lowest in "basal-like" tumors.
  • Ectopic expression of NET-6 in low-expressing MDA-MB-231 cells altered cellular morphology, inhibited growth in vitro, and decreased invasion in a Boyden chamber assay.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Membrane Proteins / analysis
  • [MeSH-minor] Antigens, CD / analysis. Antigens, CD82. Antigens, CD9. Antigens, Neoplasm / genetics. Cadherins / analysis. Cell Adhesion Molecules / genetics. Cell Line, Tumor. Cell Proliferation. Down-Regulation. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Membrane Glycoproteins / analysis. Proto-Oncogene Proteins / analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Tetraspanins

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958618.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD82; 0 / Antigens, CD9; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD82 protein, human; 0 / CD9 protein, human; 0 / CELSR2 protein, human; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / TACSTD2 protein, human; 0 / TSPAN13 protein, human; 0 / Tetraspanins; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


14. Eyden B, Moss J, Shore I, Banerjee SS: Metastatic small cell malignant melanoma: a case requiring immunoelectronmicroscopy for the demonstration of lattice-deficient melanosomes. Ultrastruct Pathol; 2005 Jan-Feb;29(1):71-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic small cell malignant melanoma: a case requiring immunoelectronmicroscopy for the demonstration of lattice-deficient melanosomes.
  • A case of metastatic malignant melanoma exhibiting small cell morphology is described.
  • The patient had had a previous primary nodular small cell melanoma.
  • The metastatic tumor was examined by conventional histology, light microscope immunohistochemistry, conventional electron microscopy, and ultrastructural immunolabeling.
  • Tumor cells were negative for S-100 protein and very focally positive for cytokeratin: these findings in combination with small cell morphology suggested the possibility of small cell carcinoma.
  • By electron microscopy, tumor cells lacked unambiguous melanosomes but contained paranuclear aggregates of nondescript granules.
  • This tumor is an uncommon example of malignant melanoma where immunoultrastructural analysis helped clarify the nature of otherwise nondescript granules as true but lattice-deficient melanosomes.
  • This is also the first case of small cell melanoma to be studied by electron microscopy.
  • [MeSH-major] Lymphatic Metastasis / pathology. Melanoma / pathology. Melanosomes / ultrastructure. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Microscopy, Electron, Transmission. Microscopy, Immunoelectron. Neoplasms, Multiple Primary / pathology. S100 Proteins / metabolism. Skin Neoplasms / metabolism. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15931781.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


15. Schulz H: [Pigmented lesion on the temple. Pigment cell tumor, basal cell carcinoma, or irritated seborrheic keratosis?]. Hautarzt; 2010 Dec;61(12):1061-2
Genetic Alliance. consumer health - Keratosis, seborrheic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pigmented lesion on the temple. Pigment cell tumor, basal cell carcinoma, or irritated seborrheic keratosis?].
  • [Transliterated title] Pigmentierte Läsion der Schläfenregion. Melanozytärer Tumor, Basalzellkarzinom oder irritierte seborrhoische Keratose?
  • The slightly raised skin tumor with well-defined margins had appeared 3 years earlier, slowly enlarging and finally changing in color.
  • Biopsy of the tumor demonstrated hyperplasia of the epidermis and normal basaloid keratinocytes partially extending into the dermis.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Facial Dermatoses / diagnosis. Facial Neoplasms / diagnosis. Keratosis, Seborrheic / diagnosis. Nevus, Pigmented / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatol Clin. 2001 Apr;19(2):347-57 [11556243.001]
  • [Cites] Arch Dermatol. 2002 Dec;138(12):1556-60 [12472342.001]
  • (PMID = 21069503.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Kazakov DV, Vittay G, Michal M, Calonje E: High-grade trichoblastic carcinosarcoma. Am J Dermatopathol; 2008 Feb;30(1):62-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we present the second case of this tumor, which, in contrast to the original example, may be classified as a high-grade neoplasm.
  • The tumor was excised, and the patient had no evidence of recurrence or metastasis 6 years after surgery.
  • Microscopically, the neoplasm demonstrated a fenestrated growth pattern with a slightly myxoid matrix in the background.
  • Despite the close association throughout the tumor, the epithelial and the stromal cells were sharply separated, without transition between both elements.
  • We view the present case and that previously reported in 2004 as authentic carcinosarcomas, and not as metaplastic (sarcomatoid) basal cell carcinomas.
  • This conclusion is reached after analyzing the embryological development of the hair follicle, its normal histology and the morphology of cutaneous adnexal tumors with follicular differentiation.
  • [MeSH-major] Carcinosarcoma / pathology. Hair Diseases / pathology. Hair Follicle / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Ear / pathology. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212548.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Allison AS, McIntyre MA, McArdle C, Habib FK: The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion. Hum Pathol; 2007 Nov;38(11):1590-602
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion.
  • This study examines the expression of the insulin-like growth factor type 1 receptor (IGF-1R) in colorectal neoplasia.
  • We show for the first time that (1) in normal colorectal crypts, epithelial stem cells in the basal crypt region express high IGF-1R levels, which decrease to low levels when these cells migrate to and differentiate in the mid and upper crypt regions;.
  • (2) in tumor initiation in aberrant crypt foci, all of the transformed cells express high levels of the IGF-1R at stem cell levels throughout the crypt axis;.
  • (3) in tumor progression in adenomatous and cancerous crypts, tumor cells of an epithelial type morphology express high levels of the IGF-1R;.
  • (4) in advanced cancers, low levels of the IGF-1R are expressed in invasive foci where cancer cells dedifferentiate to a mesenchymal-type morphology and show a loss of cell adhesion.
  • Interestingly, these cells can form an alternating pattern with mesenchymal type cells that show cell adhesion and high levels of IGF-1R expression.
  • In summary, this study shows that high-level IGF-1R expression in colorectal neoplasia is initiated by an abnormality of stem cell programmed differentiation in the aberrant crypt focus.
  • However, low-level IGF-1R expression is found in some invasive cancers where it is consequent to cancer cell dedifferentiation to a mesenchymal type morphology with loss of cell adhesion.
  • [MeSH-major] Colorectal Neoplasms / pathology. Neoplasm Invasiveness / physiopathology. Receptor, IGF Type 1

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651787.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


18. Pfaff D, Philippova M, Buechner SA, Maslova K, Mathys T, Erne P, Resink TJ: T-cadherin loss induces an invasive phenotype in human keratinocytes and squamous cell carcinoma (SCC) cells in vitro and is associated with malignant transformation of cutaneous SCC in vivo. Br J Dermatol; 2010 Aug;163(2):353-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cadherin loss induces an invasive phenotype in human keratinocytes and squamous cell carcinoma (SCC) cells in vitro and is associated with malignant transformation of cutaneous SCC in vivo.
  • Atypical glycosylphosphatidylinositol-anchored T-cadherin (T-cad) is highly expressed in the basal keratinocyte layer of skin.
  • OBJECTIVES: To define the role of T-cad in the pathogenesis of cutaneous squamous cell carcinoma (SCC) through gain-of-function and loss-of-function studies in vitro and through examination of T-cad expression patterns in human cutaneous SCC specimens in relation to histological classification of degree of tumour differentiation.
  • METHODS: In vitro studies employed lentiviral-mediated overexpression/silencing of T-cad in normal human keratinocyte (HaCaT) and SCC (A431) cell lines, monolayer and multicellular spheroid culture models, cell morphology analyses and assays of random motility and invasion.
  • Immunohistochemistry was performed on skin specimens from patients with actinic keratosis, Bowen disease or SCC.
  • RESULTS: In vitro, silencing of T-cad induced a morphologically elongated and disorganized cell phenotype, increased random motility and markedly enhanced invasive potential.
  • Overexpression of T-cad induced a morphologically spread and compact cell phenotype and blunted invasive potential.
  • However, in both categories aberrant and/or absence of T-cad expression was associated with histological features of a potentially more malignant and invasive phenotype of cutaneous SCC.
  • CONCLUSIONS: T-cad is a controlling determinant of SCC phenotype and invasive behaviour and its loss is associated with the process of malignant transformation from noninvasive to invasive SCC.
  • [MeSH-major] Cadherins / physiology. Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Keratinocytes / pathology. Neoplasm Proteins / physiology. Skin Neoplasms / pathology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Migration Assays. Fluorescent Antibody Technique. Gene Silencing. Humans. Neoplasm Invasiveness / physiopathology. Phenotype. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20394625.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / H-cadherin; 0 / Neoplasm Proteins
  •  go-up   go-down


19. Harwood CA, Proby CM, McGregor JM, Sheaff MT, Leigh IM, Cerio R: Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series. J Am Acad Dermatol; 2006 Feb;54(2):290-300
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Non-melanoma skin cancers (NMSCs) are increased in organ transplant recipients, but transplant and immunocompetent squamous and basal cell carcinomas (SCCs, BCCs) have not been compared previously in a single-center study.
  • Spindle cell morphology was more common in transplant SCCs, a superficial component was more common in transplant BCCs, and histologic features of HPV infection were overrepresented in transplant tumors.
  • Transplant SCCs, particularly those with diffuse spindle cell change, may require more aggressive management, whereas transplant BCCs do not.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Immunocompromised Host. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Case-Control Studies. Cell Differentiation. Female. Humans. Kidney Transplantation. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2006 Jun;54(6):1115 [16713490.001]
  • (PMID = 16443060.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / CRUK/ A6695
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Luebke AM, Schlomm T, Gunawan B, Bonkhoff H, Füzesi L, Erbersdobler A: Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach. Virchows Arch; 2005 Mar;446(3):338-41
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.
  • Basal cell tumours of the prostatic gland are rare, and the classification is difficult.
  • In the present case report, a large, tumour-like proliferation of atypical basaloid cells was found incidentally in a prostatectomy specimen that otherwise contained a conventional acinar adenocarcinoma.
  • However, there were no definite criteria for a malignant behaviour of the basal cell tumour.
  • Comparative genomic hybridisation from microdissected tumour cells yielded losses at the short arms of chromosomes 8 and 12 in the conventional adenocarcinoma and a normal karyotype in the basal cell tumour.
  • The pathological findings favoured the diagnosis of an atypical basal cell hyperplasia.
  • [MeSH-major] Carcinoma, Acinar Cell / complications. Carcinoma, Acinar Cell / pathology. Prostatic Hyperplasia / complications. Prostatic Hyperplasia / pathology. Prostatic Neoplasms / complications. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / pathology. Nucleic Acid Hybridization

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726402.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Evke E, Minbay FZ, Temel SG, Kahveci Z: Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval. J Mol Histol; 2009 Feb;40(1):13-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of p53 protein in basal cell skin cancer after microwave-assisted antigen retrieval.
  • p53 is the most frequently altered tumor-suppressor gene in skin cancer.
  • In contrast, the mutant p53 protein has an extended half-life in tumor cells and can be detected by immunohistochemical methods. p53 is widely used as an indicator of tumor aggression and progression.
  • This study was designed to evaluate the efficacy of different fixatives, of microwaving and microwave pretreatment method to retrieve p53 immunoreactivity in paraffin-embedded non-lesioned (adjacent normal tissue) human skin samples or pathological human skin samples diagnosed as basal cell carcinoma.
  • In this study the effects of six different fixation methods on the immunohistochemical staining have been investigated in basal cell tumor specimens.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Immunohistochemistry / methods. Microwaves. Skin Neoplasms / metabolism. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19096907.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 1HG84L3525 / Formaldehyde; 3K9958V90M / Ethanol
  •  go-up   go-down


22. Cherian P, Kumarasinghe P: Giant basal cell carcinoma masquerading as an osteogenic sarcoma. Australas J Dermatol; 2009 Feb;50(1):60-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma masquerading as an osteogenic sarcoma.
  • Superficial and deep biopsies yielded invasive basal cell carcinoma.
  • We explore the literature regarding the tumorigenic effects of peri-fracture cytokines on the biological behaviour of basal cell neoplasms.
  • [MeSH-major] Bone Neoplasms / diagnosis. Carcinoma, Basal Cell / diagnosis. Clavicle / injuries. Fractures, Bone / complications. Osteosarcoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Fractures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178496.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


23. Nikitovic D, Assouti M, Sifaki M, Katonis P, Krasagakis K, Karamanos NK, Tzanakakis GN: Chondroitin sulfate and heparan sulfate-containing proteoglycans are both partners and targets of basic fibroblast growth factor-mediated proliferation in human metastatic melanoma cell lines. Int J Biochem Cell Biol; 2008;40(1):72-83
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chondroitin sulfate and heparan sulfate-containing proteoglycans are both partners and targets of basic fibroblast growth factor-mediated proliferation in human metastatic melanoma cell lines.
  • The aim of the present study was to examine the possible participation of various glycosaminoglycans, i.e. chondroitin sulfate, dermatan sulfate and heparin on basal and FGF-2-induced growth of WM9 and M5 human metastatic melanoma cells.
  • Exogenous glycosaminoglycans mildly inhibited WM9 cell's proliferation, which was abolished by FGF-2.
  • Treatment with the specific inhibitor of the glycosaminoglycan sulfation, sodium chlorate, demonstrated that endogenous glycosaminoglycan/proteoglycan production is required for both basal and stimulated by FGF-2 proliferation of these cells.
  • Furthermore, in WM9 cells the degradation of membrane-bound chondroitin/dermatan sulfate stimulates basal growth and even enhances FGF-2 stimulation.
  • Both the amounts of chondroitin/dermatan/heparan sulfate and their sulfation levels differed between the cell lines and were distinctly modulated by FGF-2.
  • In this study, we show that chondroitin/dermatan sulfate-containing proteoglycans, likely in cooperation with heparan sulfate, participate in metastatic melanoma cell FGF-2-induced mitogenic response, which represents a novel finding and establishes the central role of sulfated glycosaminoglycans on melanoma growth.
  • [MeSH-major] Cell Proliferation. Chondroitin Sulfates / metabolism. Fibroblast Growth Factors / metabolism. Heparitin Sulfate / metabolism. Melanoma / metabolism. Proteoglycans / metabolism
  • [MeSH-minor] Autocrine Communication. Cell Differentiation. Cell Line, Tumor. Cell Transformation, Neoplastic. Glycosaminoglycans. Humans. Neoplasm Metastasis. Protein-Tyrosine Kinases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706452.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycosaminoglycans; 0 / Proteoglycans; 62031-54-3 / Fibroblast Growth Factors; 64082-61-7 / A73025; 9007-28-7 / Chondroitin Sulfates; 9050-30-0 / Heparitin Sulfate; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


24. Willberg J, Hormia M, Takkunen M, Kikkawa Y, Sekiguchi K, Virtanen I: Lutheran blood group antigen as a receptor for alpha5 laminins in gingival epithelia. J Periodontol; 2007 Sep;78(9):1810-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies indicated that Lu mediates cell adhesion to Lms-511/521 independently or in concert with integrins.
  • Cell adhesion to Lm-511/521 preparation and to pure Lm-511 was studied in quantitative cell adhesion experiments.
  • Morphological adhesion assays were carried out for visualization of the morphology and adhesion structure formation of the adhering cells.
  • RESULTS: Immunofluorescence studies on gingiva showed complete coalignment of Lu on basal epithelial cells with the BM Lm alpha5 chain.
  • A surface-confined, punctate immunoreaction for Lu was detected throughout cell surfaces on cultured gingival cells.
  • In quantitative cell adhesion assays, the adhesion of cells to both Lm alpha5 preparations was diminished with monoclonal antibodies (MAbs) against integrin alpha(3) and even more effectively with MAbs against the beta(1) subunit.
  • Lu also seemed to have a role in gingival epithelial cell adhesion together with integrin alpha(3)beta(1).
  • [MeSH-major] Cell Adhesion Molecules / metabolism. Gingiva / cytology. Laminin / metabolism. Lutheran Blood-Group System / metabolism. Neoplasm Proteins / metabolism. Receptors, Laminin / metabolism
  • [MeSH-minor] Adult. Basement Membrane. Cell Adhesion / physiology. Cell Line, Transformed. Humans. Integrin alpha3beta1 / metabolism. Keratinocytes / metabolism. Microscopy, Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760553.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAM protein, human; 0 / Cell Adhesion Molecules; 0 / Integrin alpha3beta1; 0 / Laminin; 0 / Lutheran Blood-Group System; 0 / Neoplasm Proteins; 0 / Receptors, Laminin; 0 / laminin alpha5
  •  go-up   go-down


25. Mancuso M, Leonardi S, Tanori M, Pasquali E, Pierdomenico M, Rebessi S, Di Majo V, Covelli V, Pazzaglia S, Saran A: Hair cycle-dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+ mice exposed to radiation. Cancer Res; 2006 Jul 1;66(13):6606-14
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hair cycle-dependent basal cell carcinoma tumorigenesis in Ptc1neo67/+ mice exposed to radiation.
  • We examined the effects of hair cycle phase on basal cell carcinoma (BCC) tumorigenesis induced by radiation in mice lacking one Patched allele (Ptc1(neo67/+)).
  • Our results show that Ptc1(neo67/+) mouse skin irradiated in early anagen is highly susceptible to tumor induction, as a 3.2-fold incidence of visible BCC-like tumors was observed in anagen-irradiated compared with telogen-irradiated mice.
  • In fact, in addition to typical BCC-like tumors, we observed development of a distinct basal cell tumor subtype characterized by anti-cytokeratin 14 and anti-smooth muscle actin reactivity.
  • In contrast, there are strong indications for the derivation of typical, smooth muscle actin-negative BCC-like tumors from cell progenitors of interfollicular epidermis.
  • These results underscore the role of follicular bulge stem cells and their progeny with high self-renewal capacity in the formation of basal cell tumors and contribute to clarify the relationship between target cell and tumor phenotype in BCC tumorigenesis induced by radiation.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Hair Follicle / radiation effects. Neoplasms, Radiation-Induced / etiology. Receptors, Cell Surface / genetics. Skin Neoplasms / etiology
  • [MeSH-minor] Allelic Imbalance. Animals. Cell Lineage. Female. Kruppel-Like Transcription Factors / biosynthesis. Kruppel-Like Transcription Factors / genetics. Loss of Heterozygosity. Male. Mice. Skin / radiation effects. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818633.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gli protein, mouse; 0 / Gli2 protein; 0 / Kruppel-Like Transcription Factors; 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


26. Paradela S, Pita-Fernández S, Peña C, Fernández-Jorge B, García-Silva J, Mazaira M, Fonseca E: Complications of ambulatory major dermatological surgery in patients older than 85 years. J Eur Acad Dermatol Venereol; 2010 Oct;24(10):1207-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent tumour was basal cell carcinoma (45.1%), followed by squamous cell carcinoma (38.7%) and melanoma (8.3%).
  • [MeSH-major] Ambulatory Surgical Procedures / adverse effects. Dermatologic Surgical Procedures. Skin / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Cellulitis / etiology. Cellulitis / pathology. Female. Humans. Male. Melanoma / surgery. Necrosis / etiology. Necrosis / pathology. Retrospective Studies. Spain. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal of the European Academy of Dermatology and Venereology © 2010 European Academy of Dermatology and Venereology.
  • (PMID = 20337810.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


27. Uphoff J, Woziwodzki J, Schattka SO, Kollias A: [Loss of differentiation of a prostate adenocarcinoma after hormone therapy: the example of a metastasis in the spongy body of the penis]. Aktuelle Urol; 2008 Sep;39(5):373-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastases in the penis only occur at an advanced state of the tumour and with a high dedifferentiation, e. g., ductal adenocarcinoma.
  • Changes in the morphology of the prostate carcinoma are specially known for the occurrence of small-cell neuroendocrine and undifferentiated carcinomas.
  • At this state of the disease, there is only the possibility of a palliative therapy with a poor prognosis.
  • The increasing histological dedifferentiation of the tumour tissue can make it difficult or even impossible to identify the primary lesion.
  • [MeSH-major] Adenocarcinoma / secondary. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoma, Basal Cell / secondary. Carcinoma, Transitional Cell / secondary. Cell Transformation, Neoplastic / pathology. Diphosphonates / therapeutic use. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Neoplasms, Multiple Primary / drug therapy. Penile Neoplasms / secondary. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biopsy. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Combined Modality Therapy. Cystectomy. Diagnosis, Differential. Disease Progression. Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Penis / pathology. Penis / surgery. Prostate / pathology. Prostate / surgery. Prostatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798127.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Diphosphonates; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


28. Mihashi H, Kawahara A, Kage M, Kojiro M, Nakashima T, Umeno H, Sakamoto K, Chiziwa H: Comparison of preoperative fine-needle aspiration cytology diagnosis and histopathological diagnosis of salivary gland tumors. Kurume Med J; 2006;53(1-2):23-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rates of agreement in the diagnosis of pleomorphic adenoma, Warthin tumor, and basal cell adenoma were 96%, 92.9%, and 55.5%, respectively.
  • The rate of agreement of histopathological types in the malignant tumors was 30%.
  • However, this study exposed several problems which are the inadequate sampling rate and the difficulty in diagnosing malignant tumors.
  • [MeSH-major] Salivary Gland Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043392.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


29. Xu E, Wang X, Hao Z, Chen Z, Lu X: Germinoma in the basal ganglia with an abnormal karyotype: case report and review of the literature. Childs Nerv Syst; 2010 May;26(5):707-12
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germinoma in the basal ganglia with an abnormal karyotype: case report and review of the literature.
  • INTRODUCTION: Germ cell tumor of basal ganglia with abnormal constitutional karyotype has been rarely reported.
  • Magnetic resonance imaging showed high intensity on T1-weighted, T2-weighted, and contrast-enhanced T1-weighted images in the left basal ganglia and ipsilateral cerebral hemiatrophy predominantly in the basal ganglia and midbrain.
  • Germinoma in the left basal ganglia was confirmed by stereotactic biopsy and immunochemical examination.
  • His constitutional karyotype was 46, XY, t (8; 19), (p23.1; p13.1), a novel chromosomal abnormality.
  • DISCUSSION: Intracranial germinoma, a potentially curable tumor, should be considered in children with nonspecific neurological symptoms, endocrinologic changes, and ipsilateral cerebral hemiatrophy on computed tomography or magnetic resonance.
  • Investigation of chromosomal aberrations in those patients would clarify the tumorigenesis and lead to possibilities for novel disease-specific therapies.
  • [MeSH-major] Basal Ganglia Diseases / genetics. Brain Neoplasms / genetics. Germinoma / genetics

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876633.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


30. Kopriva I, Persin A: Unsupervised decomposition of low-intensity low-dimensional multi-spectral fluorescent images for tumour demarcation. Med Image Anal; 2009 Jun;13(3):507-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unsupervised decomposition of low-intensity low-dimensional multi-spectral fluorescent images for tumour demarcation.
  • Such situation arises when low-dimensional low-intensity multi-spectral image of the tumour in the early stage of development is represented by the SLMM, wherein tumour is spectrally similar to the surrounding tissue.
  • The original contribution of this paper is in proposing an algorithm for unsupervised decomposition of low-dimensional multi-spectral image for high-contrast tumour visualisation.
  • We demonstrate good performance of the method on both computational model and experimental low-intensity red-green-blue fluorescent image of the surface tumour (basal cell carcinoma).
  • [MeSH-major] Algorithms. Artificial Intelligence. Image Interpretation, Computer-Assisted / methods. Microscopy, Fluorescence / methods. Pattern Recognition, Automated / methods. Skin Neoplasms / pathology. Spectrometry, Fluorescence / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282233.001).
  • [ISSN] 1361-8423
  • [Journal-full-title] Medical image analysis
  • [ISO-abbreviation] Med Image Anal
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


31. Abedalthagafi M, Rushing EJ, Auerbach A, Desouki MM, Marwaha J, Wang Z, Fanburg-Smith JC: Sporadic cutaneous angiosarcomas generally lack hypoxia-inducible factor 1alpha: a histologic and immunohistochemical study of 45 cases. Ann Diagn Pathol; 2010 Feb;14(1):15-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous angiosarcoma (AS) is a rare malignant neoplasm of dermis composed of infiltrating cells of endothelial phenotype with overall poor prognosis.
  • Associated basal cell carcinoma was noted in 1 patient; no others had other neoplasms or unrelated surgeries.
  • Epithelioid morphology was present in 29% (n = 13) cases.
  • CD31 highlighted malignant endothelial cells.
  • Treatment and follow-up data were only available on 4 cases: 2 died of disease within 4 years, 2 others had known recurrence within 2 years.
  • Absence of SMA can prove extravascular extension of tumor, outside their normal vessel confines.
  • [MeSH-major] Dermis / metabolism. Hemangiosarcoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Neovascularization, Pathologic / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anoxia / metabolism. Anoxia / pathology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20123452.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


32. Liu SC, Jen YM, Jiang SS, Chang JL, Hsiung CA, Wang CH, Juang JL: G(alpha)12-mediated pathway promotes invasiveness of nasopharyngeal carcinoma by modulating actin cytoskeleton reorganization. Cancer Res; 2009 Aug 1;69(15):6122-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study investigating these mechanisms, guanine nucleotide-binding protein alpha(12) subunit (G(alpha)(12)) signaling was found by microarray analysis to be increased in primary NPC cells and NPC-derived cell lines.
  • Using small interfering RNA to knock down G(alpha)(12) in NPC cells resulted in a reduction in cell migration and invasion as well as a reversal in fibroblastoid morphology.
  • Knocking down one of those genes, IQ motif containing GTPase activating protein 1, reduced the migration and formation of adherens junctions and reversed the fibroblastoid morphology of NPC cells, as knocking down G(alpha)(12) was found to do.
  • Immunohistochemical analysis found NPC tumors to have significantly greater levels of G(alpha)(12) protein than the normal basal epithelial cells.
  • [MeSH-major] Actins / metabolism. Cytoskeleton / metabolism. GTP-Binding Protein alpha Subunits, G12-G13 / metabolism. Nasopharyngeal Neoplasms / metabolism
  • [MeSH-minor] Cell Movement / physiology. Down-Regulation. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lymphatic Metastasis. Microarray Analysis. Neoplasm Invasiveness. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Small Interfering / genetics. Signal Transduction. Transfection. Tumor Cells, Cultured. ras GTPase-Activating Proteins / biosynthesis. ras GTPase-Activating Proteins / genetics. ras GTPase-Activating Proteins / metabolism

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19602597.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / IQ motif containing GTPase activating protein 1; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / ras GTPase-Activating Proteins; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, G12-G13
  •  go-up   go-down


33. Zepeda-Castilla EJ, Recinos-Money E, Cuéllar-Hubbe M, Robles-Vidal CD, Maafs-Molina E: [Molecular classification of breast cancer]. Cir Cir; 2008 Jan-Feb;76(1):87-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Clasificación molecular del cáncer de mama.
  • Breast cancer is classified based on clinical stage, cellular morphology and immunohistochemical analysis.
  • ER- tumors also include two subtypes, the HER2+ and the basal type.
  • These subtypes differ in their biology and both demonstrate short disease-free periods after treatment and poorer outcome.
  • [MeSH-major] Breast Neoplasms / classification. Gene Expression Profiling
  • [MeSH-minor] Cell Division / genetics. Cell Transformation, Neoplastic / genetics. DNA, Complementary / genetics. DNA, Neoplasm / genetics. Female. Forecasting. Genes, erbB-2. Humans. Kaplan-Meier Estimate. Mexico / epidemiology. Models, Biological. Oligonucleotide Array Sequence Analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Estrogen / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492427.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA, Neoplasm; 0 / Receptors, Estrogen; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 42
  •  go-up   go-down


34. Tsai TM, Wu YH, Yang KC, Yang CY, Tsai TH, Chan JY: Sebaceous carcinoma associated with seborrheic keratosis. J Cutan Med Surg; 2010 Sep-Oct;14(5):240-4
Genetic Alliance. consumer health - Keratosis, seborrheic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of a seborrheic keratosis with other common cutaneous neoplasms such as basal cell carcinoma and Bowen disease has been reported, but the association between a seborrheic keratotis and a malignant neoplasm with sebaceous differentiation is very unusual.
  • OBJECTIVE: We present a case of two contiguous neoplasms, a seborrheic keratosis and a sebaceous carcinoma, and discuss the possibility of malignant change in a seborrheic keratosis as an explanation for the findings.
  • METHODS AND RESULTS: A 57-year-old man presented with an asymptomatic tumor on the skin of his abdomen that was composed of two separate but contiguous lesions.
  • CONCLUSION: Although the association is likely to be a coincidence and probably represents a collision tumor, the possibility that the sebaceous carcinoma represents malignant degeneration of the seborrheic keratosis cannot be entirely excluded.
  • [MeSH-major] Keratosis, Seborrheic / pathology. Sebaceous Gland Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20868621.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Aragaki T, Michi Y, Katsube K, Uzawa N, Okada N, Akashi T, Amagasa T, Yamaguchi A, Sakamoto K: Comprehensive keratin profiling reveals different histopathogenesis of keratocystic odontogenic tumor and orthokeratinized odontogenic cyst. Hum Pathol; 2010 Dec;41(12):1718-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive keratin profiling reveals different histopathogenesis of keratocystic odontogenic tumor and orthokeratinized odontogenic cyst.
  • Keratocystic odontogenic tumor is a cystic lesion that behaves more aggressively than other jaw cysts.
  • In neonatal rat tooth germ, cells strongly positive for keratin 17 and keratin 19 were observed, specifically in the dental lamina, implying the origin of keratocystic odontogenic tumor.
  • GLI2, a downstream effector of hedgehog signaling, was significantly expressed in keratocystic odontogenic tumor and basal cell carcinoma, accompanied with robust expression of keratin 17, mammalian target of rapamycin, and BCL2.
  • These findings provide evidence to support the viewpoint that keratocystic odontogenic tumor and orthokeratinized odontogenic cyst are separate entities, and furthermore suggest their characteristic histology, pathogenesis, and biological behaviors.
  • [MeSH-major] Jaw Neoplasms / metabolism. Keratins / metabolism. Membrane Proteins / metabolism. Odontogenic Cysts / metabolism. Odontogenic Tumors / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Animals, Newborn. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Child. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Kruppel-Like Transcription Factors / metabolism. Male. Middle Aged. Nuclear Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rats. TOR Serine-Threonine Kinases / metabolism. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20801488.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI2 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Membrane Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / loricrin; 68238-35-7 / Keratins; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  •  go-up   go-down


36. Wright MH, Robles AI, Herschkowitz JI, Hollingshead MG, Anver MR, Perou CM, Varticovski L: Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1. Mol Cancer; 2008 Apr 07;7:29
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently showed that transplantation of transgenic mammary tumors as cell suspensions into naïve recipients generates reproducible tumors with remarkable stability of gene expression profile.
  • We examined the expression profiles of original and serially transplanted mammary tumors from Brca1 deficient mice, and tumor derived cell lines to validate their use for preclinical testing and studies of tumor biology.
  • METHODS: Original tumors, serially transplanted and multiple cell lines derived from Brca1 mammary tumors were characterized by morphology, gene and protein expression, and cell surface markers.
  • Gene expression data segregated Brca1 tumors into 3 distinct types: basal, mixed luminal, and tumors with epithelial-to-mesenchymal transition (EMT).
  • Serial transplantation of individual tumors and multiple cell lines derived from the original tumors recapitulated the molecular characteristics of each tumor of origin.
  • One tumor had distinct features of EMT and gave rise to cell lines that contained a distinct CD44+/CD24-/low population that may correlate with human breast cancer stem cells.
  • However, cell lines offer a robust material for understanding tumor biology and response to therapies driven by BRCA1 deficiency.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] Oncogene. 2003 Aug 21;22(35):5415-26 [12934101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Science. 2003 Oct 24;302(5645):643-6 [14576434.001]
  • [Cites] Lancet. 1994 Mar 19;343(8899):692-5 [7907678.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1222-7 [9102202.001]
  • [Cites] Cell. 1997 Aug 8;90(3):425-35 [9267023.001]
  • [Cites] Oncogene. 1998 Dec 17;17(24):3115-24 [9872327.001]
  • [Cites] Nat Genet. 1999 May;22(1):37-43 [10319859.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1257-63 [15809716.001]
  • [Cites] Breast Cancer Res. 2005;7(4):143-8 [15987465.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] Mol Cancer Res. 2005 Oct;3(10):531-9 [16254187.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8006-14 [16299229.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Nucleic Acids Res. 2006;34(5):1416-26 [16522651.001]
  • [Cites] Breast Cancer Res. 2006;8(1):R7 [16417656.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1183-9 [16731750.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5864-74 [16998501.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5885-97 [16998503.001]
  • [Cites] Clin Cancer Res. 2006 Nov 1;12(21):6547-56 [17085670.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):867-76 [17307353.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2168-77 [17404101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6 [17626182.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8065-80 [17804718.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8131-8 [17804725.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11811-20 [18089811.001]
  • [Cites] Chem Biol Interact. 2008 Jan 30;171(2):159-64 [17362899.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Oncogene. 2000 Feb 21;19(8):1059-64 [10713690.001]
  • [Cites] Nat Med. 2001 May;7(5):552-6 [11329055.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):266-71 [11431698.001]
  • [Cites] Oncogene. 2002 Aug 1;21(33):5097-107 [12140760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • (PMID = 18394172.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-101227-01; United States / NCI NIH HHS / CA / P50-CA58223-09A1; United States / NCI NIH HHS / CA / R01 CA101227; United States / NCI NIH HHS / CA / P50 CA058223; United States / PHS HHS / / N01-C0-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2329667
  •  go-up   go-down


37. Li LJ, Li Y, Wen YM, Liu H, Zhao HW: Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol; 2008 Feb;44(2):187-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of salivary gland tumor cases in West China in past 50 years.
  • In our study, 3461 cases of salivary gland tumor treated between 1955 and 2002 at West China Stomatology Hospital of Sichuan University were retrospectively analyzed, and compared with the previous reports.
  • Measures such as age, tumor location, tumor histological type, and the nature of the growth (benign or malignant) were recorded at the same time.
  • The findings are as follows: the average ages of salivary gland tumor patients were 41.38 years for the benign cases and 45.20 for the malignant ones; the male:female ratio was 0.
  • 99:1 in the benign cases and 1.34:1 in the malignant ones; primary tumors were mostly in the parotid gland, palate and submandibular gland in sequence.
  • Pleomorphic adenoma was the most frequent benign tumor followed by Warthin's tumor and basal cell adenoma, whereas mucoepidermoid carcinoma, adenoid cystic carcinoma and adenocarcinoma not otherwise specified were the most frequent malignant tumors.
  • The male:female ratio of malignant tumors was higher than that of benign ones.
  • Pleomorphic adenoma and mucoepidermoid carcinoma were the most frequent benign and malignant tumors, respectively.
  • [MeSH-major] Adenoma, Pleomorphic / epidemiology. Carcinoma, Mucoepidermoid / epidemiology. Salivary Gland Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenolymphoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / pathology. Child. Child, Preschool. China / epidemiology. Female. Humans. Incidence. Infant. Male. Middle Aged. Palatal Neoplasms / pathology. Parotid Neoplasms / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oral Oncol. 2011 Sep;47(9):929-30
  • (PMID = 17418612.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Rudolph J, Berl J, Hamm B, Klingebiel R: Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy. Acta Radiol; 2006 Mar;47(2):205-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of basal cell adenoma in Curschmann-Steinert myotonic dystrophy.
  • We present the magnetic resonance imaging in the unusual combination of a patient with known myotonic dystrophy and recurrent basal cell tumor.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Basal Cell / diagnosis. Head and Neck Neoplasms / diagnosis. Magnetic Resonance Imaging. Myotonic Dystrophy / pathology

  • Genetic Alliance. consumer health - Myotonic dystrophy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604969.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


39. Gonzalez-Quevedo R, Shoffer M, Horng L, Oro AE: Receptor tyrosine phosphatase-dependent cytoskeletal remodeling by the hedgehog-responsive gene MIM/BEG4. J Cell Biol; 2005 Jan 31;168(3):453-63
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During development, dynamic remodeling of the actin cytoskeleton allows the precise placement and morphology of tissues.
  • We previously identified Basal cell carcinoma-enriched gene 4 (BEG4)/Missing in Metastasis (MIM), a Shh-inducible, Wiskott-Aldrich homology 2 domain-containing protein that potentiates Gli transcription (Callahan, C.A., T. Ofstad, L.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1993 Dec 10;262(5140):1731-4 [8259518.001]
  • [Cites] Cell. 1992 May 1;69(3):385-7 [1581959.001]
  • [Cites] Cell. 1994 Jul 29;78(2):291-301 [8044841.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 2):2061-9 [7806582.001]
  • [Cites] J Biol Chem. 1995 Mar 24;270(12):6722-8 [7896816.001]
  • [Cites] EMBO J. 1995 Jun 15;14(12):2827-38 [7796809.001]
  • [Cites] Dev Dyn. 1997 Jan;208(1):48-61 [8989520.001]
  • [Cites] Curr Opin Cell Biol. 1998 Feb;10(1):23-34 [9484592.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):9570-6 [9545287.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15611-20 [9624153.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • [Cites] Neuron. 1999 Feb;22(2):301-12 [10069336.001]
  • [Cites] Science. 1999 Jul 16;285(5426):403-6 [10411502.001]
  • [Cites] Trends Genet. 1999 Oct;15(10):418-25 [10498938.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5274-84 [10508161.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2724-9 [15545630.001]
  • [Cites] J Cell Biol. 2000 Jun 26;149(7):1455-72 [10871285.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2000;29:545-76 [10940259.001]
  • [Cites] Cell. 2000 Aug 4;102(3):377-85 [10975527.001]
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):732-5 [11130076.001]
  • [Cites] J Cell Sci. 2001 Jan;114(Pt 1):3-4 [11112680.001]
  • [Cites] Curr Opin Cell Biol. 2001 Apr;13(2):158-66 [11248549.001]
  • [Cites] Nat Cell Biol. 2001 May;3(5):484-91 [11331876.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2065-76 [11493642.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36163-7 [11500485.001]
  • [Cites] Cell. 2001 Sep 21;106(6):759-69 [11572781.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12521-6 [11592978.001]
  • [Cites] Nature. 2001 Oct 25;413(6858):797-803 [11677596.001]
  • [Cites] Front Biosci. 2002 Apr 1;7:d918-69 [11897562.001]
  • [Cites] Neuron. 2002 Mar 28;34(1):27-38 [11931739.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2670-8 [11965540.001]
  • [Cites] Science. 2002 May 31;296(5573):1644-6 [12040179.001]
  • [Cites] Annu Rev Biochem. 2002;71:755-81 [12045110.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:601-35 [12142283.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:247-88 [12142287.001]
  • [Cites] Physiol Rev. 2003 Jan;83(1):1-24 [12506125.001]
  • [Cites] J Cell Biol. 2003 Feb 3;160(3):409-21 [12566431.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8452-9 [12482861.001]
  • [Cites] Biochem J. 2003 Apr 15;371(Pt 2):463-71 [12570871.001]
  • [Cites] Cell. 2003 Apr 4;113(1):11-23 [12679031.001]
  • [Cites] Cell. 2003 Apr 4;113(1):37-47 [12679033.001]
  • [Cites] J Cell Sci. 2003 Jun 15;116(Pt 12):2577-83 [12734400.001]
  • [Cites] EMBO Rep. 2003 Aug;4(8):761-5 [12897799.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6909-21 [12972609.001]
  • [Cites] Dev Biol. 2003 Sep 15;261(2):520-36 [14499657.001]
  • [Cites] Curr Opin Genet Dev. 2003 Oct;13(5):513-21 [14550418.001]
  • [Cites] Neuroscientist. 2003 Oct;9(5):343-53 [14580119.001]
  • [Cites] J Cell Biol. 2003 Dec 8;163(5):1045-55 [14657236.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):964-72 [14661054.001]
  • [Cites] J Biol Chem. 2004 Apr 9;279(15):14929-36 [14752106.001]
  • [Cites] Science. 2004 May 28;304(5675):1301-5 [15166374.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9636-41 [15210969.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Aug;5(8):635-46 [15366707.001]
  • [Cites] Cell. 1980 Jul;20(3):839-47 [6893424.001]
  • [Cites] J Biol Chem. 1990 Feb 15;265(5):2896-902 [2154464.001]
  • [Cites] Science. 1991 May 24;252(5009):1162-4 [2031185.001]
  • [Cites] Trends Biochem Sci. 1991 Mar;16(3):87-92 [2058002.001]
  • [Cites] Science. 1993 Dec 10;262(5140):1734-7 [8259519.001]
  • (PMID = 15684034.001).
  • [ISSN] 0021-9525
  • [Journal-full-title] The Journal of cell biology
  • [ISO-abbreviation] J. Cell Biol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / P01 AR044012; United States / NIAMS NIH HHS / AR / R01 AR046786; United States / NIAMS NIH HHS / AR / AR046786; United States / NIAMS NIH HHS / AR / P01AR44012
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / GAP-43 Protein; 0 / Homeodomain Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / LIM-Homeodomain Proteins; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / Mtss1 protein, mouse; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Phosphatidylinositol 4,5-Diphosphate; 0 / Proteins; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0 / insulin gene enhancer binding protein Isl-1; 0 / patched receptors; 3WHH0066W5 / Vanadates; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Ptprd protein, mouse; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 2
  • [Other-IDs] NLM/ PMC2171717
  •  go-up   go-down


40. Zhang H, Yan J, Li Y, Zhang P: Mucoepidermoid carcinoma of the eyelid: a case report and review of the literature. Yan Ke Xue Bao; 2005 Sep;21(3):152-7
Genetic Alliance. consumer health - Mucoepidermoid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He underwent tumor resection and reconstruction of the eyelid.
  • By histopathology, tumor cells showed an admixture of epidermoid and mucus-secreting cells, which was consistent with mucoepidermoid carcinoma.
  • Mucoepidermoid carcinoma is a common malignant tumor of the salivary glands, but rare in the eye tissues among which conjunctiva and lacrimal gland are most commonly involved.
  • It has a higher degree of malignancy than basal cell carcinoma and squamous cell carcinoma.
  • It should be differentiated from other neoplasms such as basal cell carcinoma and squamous cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162853.001).
  • [ISSN] 1000-4432
  • [Journal-full-title] Yan ke xue bao = Eye science
  • [ISO-abbreviation] Yan Ke Xue Bao
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 23
  •  go-up   go-down


41. Bidinotto LT, Spinardi-Barbisan AL, Rocha NS, Salvadori DM, Barbisan LF: Effects of ginger (Zingiber officinale Roscoe) on DNA damage and development of urothelial tumors in a mouse bladder carcinogenesis model. Environ Mol Mutagen; 2006 Oct;47(8):624-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, Groups G2, G3, and G6 were fed diets containing 1, 2, and 2% ginger extract, respectively, while Groups G1, G4, G5, and G7 were fed basal diet.
  • At the end of the experiment, the urinary bladder was removed, fixed, and prepared for histopathological, cell proliferation, and apoptosis evaluations.
  • The incidence and multiplicity of simple and nodular hyperplasia and transitional cell carcinoma (TCC) were increased by the BBN/MNU treatment, but dietary ginger had no significant effect on these responses.
  • [MeSH-major] Anticarcinogenic Agents / pharmacology. DNA Damage / drug effects. Ginger. Urologic Neoplasms / prevention & control
  • [MeSH-minor] Animals. Butylhydroxybutylnitrosamine / toxicity. Disease Models, Animal. Male. Methylnitrosourea / toxicity. Mice. Neoplasm Invasiveness. Plant Extracts / pharmacology. Urinary Bladder Neoplasms / chemically induced. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / prevention & control

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16878317.001).
  • [ISSN] 0893-6692
  • [Journal-full-title] Environmental and molecular mutagenesis
  • [ISO-abbreviation] Environ. Mol. Mutagen.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Plant Extracts; 3817-11-6 / Butylhydroxybutylnitrosamine; 684-93-5 / Methylnitrosourea
  •  go-up   go-down


42. Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL: A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proc Natl Acad Sci U S A; 2009 Aug 18;106(33):14028-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interference with Par6 signaling blocked TGFbeta-dependent loss of polarity in acini-like structures formed by non-transformed mammary cells grown in three-dimensional structures and suppressed the protrusive morphology of mesenchymal-like invasive mammary tumor cells without rescuing E-cadherin expression.
  • Moreover, blockade of Par6 signaling in an in vivo orthotopic model of metastatic breast cancer induced the formation of ZO-1-positive epithelium-like structures in the primary tumor and suppressed metastasis to the lungs.
  • Analysis of the pathway in tissue microarrays of human breast tumors further revealed that Par6 activation correlated with markers of the basal carcinoma subtype in BRCA1-associated tumors.
  • These studies thus reveal a key role for polarity signaling and the control of morphologic transformation in breast cancer metastasis.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Gene Expression Regulation, Neoplastic. Mammary Neoplasms, Animal / metabolism. Mammary Neoplasms, Animal / pathology. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Animals. Disease Progression. Female. Genes, BRCA1. Humans. Mice. Mice, Inbred BALB C. Microscopy, Fluorescence / methods. Neoplasm Metastasis. Signal Transduction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Mar 11;307(5715):1603-9 [15761148.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1551-9 [12070302.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5764-74 [16123809.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):548-58 [16098727.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):239-46 [16404434.001]
  • [Cites] Curr Opin Cell Biol. 2006 Apr;18(2):206-12 [16490351.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 [14519755.001]
  • [Cites] Breast Cancer Res Treat. 2009 Sep;117(1):183-91 [18563556.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):205-16 [12242153.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):807-21 [14557817.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1257-62 [14739340.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):41557-62 [15292221.001]
  • [Cites] J Natl Cancer Inst. 1972 Sep;49(3):735-49 [4647494.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):381-9 [8393616.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5041-6 [10519421.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9002-11 [15604265.001]
  • [Cites] J Cell Physiol. 2006 Jul;208(1):141-8 [16607610.001]
  • [Cites] Nat Cell Biol. 2006 Nov;8(11):1235-45 [17060907.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):435-57 [16951986.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):75-84 [17210685.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10069-74 [17537911.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1680-5 [18230721.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):989-97 [18281472.001]
  • [Cites] Cell. 2008 Apr 4;133(1):66-77 [18394990.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8201-9 [18922891.001]
  • [Cites] Oncogene. 2008 Nov 24;27(55):6878-87 [19029931.001]
  • [Cites] Cell. 2008 Nov 28;135(5):865-78 [19041750.001]
  • [Cites] Cell Res. 2009 Jan;19(1):89-102 [19050696.001]
  • [Cites] Breast Cancer Res Treat. 2009 Feb;113(3):411-22 [18327637.001]
  • [Cites] J Cell Sci. 2005 Jul 1;118(Pt 13):2859-69 [15976445.001]
  • (PMID = 19667198.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / PARD6A protein, human; 0 / Par6 protein, mouse; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2729014
  •  go-up   go-down


43. Ishihara K, Saida T, Otsuka F, Yamazaki N, Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society: Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. Int J Clin Oncol; 2008 Feb;13(1):33-41
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
  • BACKGROUND: In the previous report of the Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, we tabulated data on patients with malignant melanoma who had been registered at major medical institutions (22 institutions on average) in Japan over 5-year periods from 1987 to 1991 (group A) and from 1992 to 1996 (group B).
  • Because the International Union Against Cancer (UICC) TNM and stage classifications for malignant melanoma were changed substantially in 2002, analyses in the present investigation were performed according to the new classifications.
  • In addition, the numbers of patients with various kinds of skin malignancies, including not only malignant melanoma but also basal cell carcinoma, squamous cell carcinoma, mycosis fungoides, actinic keratosis, Bowen's disease, and Paget's disease, registered at approximately 100 medical institutions in Japan from 1987 to 2001, were also investigated and data were tabulated.
  • RESULTS: The nationwide survey of Japanese patients with malignant skin tumors from 1987 to 2001 showed that the most prevalent skin tumor was basal cell carcinoma, which increased year by year, followed by squamous cell carcinoma, and then by malignant melanoma.
  • For patients in stage III, the overall survival rate was higher in group C than that in group A or B, while there was no apparent difference in survival between the groups for patients in stage I or II.
  • For patients in stage IV, the survival rate in group C was slightly lower than that in group A or B. (7) In group C, the overall survival rates for substages III A, B, and C were ranked as III A > III B > III C. (8) The overall survival rates for stage IV M1a, M1b, and M1c were ranked as M1a > M1b > M1c.
  • CONCLUSION: In Japan, the number of patients with malignant skin tumors has increased year by year.
  • The prognosis of patients with advanced malignant melanoma remains extremely poor, but that of patients in stage III has shown an improvement.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307017.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


44. Othman M, Basturk O, Groisman G, Krasinskas A, Adsay NV: Squamoid cyst of pancreatic ducts: A distinct type of cystic lesion in the pancreas. Am J Surg Pathol; 2007 Feb;31(2):291-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinicopathologic features of a hitherto unrecognized cystic tumor of the pancreas are documented, and its possible relationship to a more common incidental microscopic lesion is analyzed.
  • The cells forming the basal/parabasal region expressed p63 (transitional/squamous cell marker, not detected in any normal pancreas or nonsquamous neoplasia) and the surface cells were positive for MUC 1 and MUC 6 (markers present in intercalated duct cells), and negative for GLUT-1 (consistent marker of serous adenomas).
  • These microcysts were found lying within compact acinar tissue, and appeared to be transforming from intercalated ducts, some focally connected to acinar elements, and they had abortive (nonbridging) septae with pseudo-loculated appearance, irregular contours and often showed tightly packed clusters of ducts with similar morphology described in the cases underwent resection specifically for this cyst type.
  • In conclusion, the distinctive morphologic, immunophenotypic, and clinical characteristics of this cystic lesion warrant its classification as a separate entity.
  • [MeSH-minor] Aged. Antigens, Neoplasm / metabolism. Dilatation, Pathologic / metabolism. Dilatation, Pathologic / pathology. Dilatation, Pathologic / surgery. Female. Humans. Male. Middle Aged. Mucin-1. Mucin-6. Mucins / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255775.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101936
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MUC1 protein, human; 0 / MUC6 protein, human; 0 / Mucin-1; 0 / Mucin-6; 0 / Mucins
  •  go-up   go-down


45. Salim C, Boxberg YV, Alterio J, Féréol S, Nothias F: The giant protein AHNAK involved in morphogenesis and laminin substrate adhesion of myelinating Schwann cells. Glia; 2009 Apr 1;57(5):535-49
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AHNAK silencing by siRNA interference affects SC morphology and laminin-substrate attachment, as well as expression and distribution of dystroglycan.
  • These findings are of high interest regarding the importance of SC-basal lamina interactions for myelination and myelin maintenance, and open up new perspectives for investigations of the molecular mechanisms underlying demyelinating neuropathies.
  • [MeSH-major] Cell Adhesion. Laminin / metabolism. Membrane Proteins / metabolism. Neoplasm Proteins / metabolism. Schwann Cells / physiology
  • [MeSH-minor] Animals. Animals, Newborn. Cell Count. Cell Differentiation. Cells, Cultured. Dystroglycans / metabolism. Gene Silencing. Mice. Mice, Inbred C57BL. Myelin Sheath / physiology. RNA, Messenger / metabolism. RNA, Small Interfering. Rats. Rats, Wistar. Receptors, Laminin / metabolism. Sciatic Nerve / growth & development. Sciatic Nerve / physiology. Sciatic Nerve / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18837049.001).
  • [ISSN] 1098-1136
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ahnak protein, mouse; 0 / Ahnak protein, rat; 0 / Laminin; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Laminin; 146888-27-9 / Dystroglycans
  •  go-up   go-down


46. Yamaguchi R, Tanaka M, Yamaguchi M, Fukushima T, Kaneko Y, Otsuka H, Isobe S, Terasaki H, Nakashima O, Kage M, Yano H: Pleomorphic carcinoma of the breast in a 17-year-old woman. Med Mol Morphol; 2010 Mar;43(1):43-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Macroscopically, the tumor was cystic, composed of a mixture of solid and myxomatous areas.
  • Histologically, the tumor exhibited ductal structures and areas with squamoid features.
  • These findings suggest an undifferentiated cancer whose cells have multilineage potential to differentiate into mesenchymal, basal, and squamoid cells, and it was diagnosed as pleomorphic carcinoma, which is a histological type hitherto unreported in young girls.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Myoepithelioma / diagnosis. Rhabdoid Tumor / diagnosis
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20340005.001).
  • [ISSN] 1860-1499
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Wiatr M, Składzieiń J: [Own experiences in treatment of the external and middle ear tumors from data collected between 1992-2001]. Przegl Lek; 2007;64(7-8):462-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We discuss a retrospective study of patients with malignant tumors of the external and middle ear operated at the Otolaryngology Department of the Jagiellonian University in Cracow between 1992-2001.
  • We performed 56 operations of malignant lesions in that period of time.
  • In our population the most common tumor was basal cell carcinoma located on the auricle in T1 stage.
  • The most common lesion located in the middle ear or middle and external ear was the squamous cell carcinoma in T2 stage.
  • [MeSH-major] Carcinoma, Basal Cell. Carcinoma, Squamous Cell. Ear Neoplasms / pathology. Ear Neoplasms / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Ear, External / surgery. Ear, Middle / surgery. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409345.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


48. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA: Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res; 2006 Aug 1;66(15):7589-97
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis.
  • p63, a homologue of the tumor suppressor p53, is critical for the development and maintenance of squamous epithelia. p63 is specifically expressed in the basal layers of stratified epithelial tissues and is considered a specific marker for cells of this type.
  • Numerous studies have highlighted the oncogenic potential of the predominant p63 isoform DeltaNp63alpha; however, data suggest that other p63 proteins can act as tumor suppressors or alter the metastatic potential of tumors.
  • Disruption of p63 in squamous cell lines resulted in down-regulation of transcripts specifically expressed in squamous tissues and a significant alteration of keratinocyte differentiation.
  • Furthermore, loss of p63 expression was accompanied by a shift toward mesenchymal morphology and an increase in motility in primary keratinocytes and squamous cell lines.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Cell Movement / physiology. DNA-Binding Proteins / deficiency. Trans-Activators / deficiency. Tumor Suppressor Proteins / deficiency
  • [MeSH-minor] Cell Differentiation / genetics. Cell Differentiation / physiology. Cell Line, Tumor. Epithelium / metabolism. Epithelium / pathology. Epithelium / physiology. Humans. Keratinocytes / pathology. Mesoderm / metabolism. Mesoderm / pathology. Mesoderm / physiology. Neoplasm Invasiveness. Neoplasm Metastasis. Transcription Factors. Transfection. Up-Regulation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885358.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 009385; United States / NCI NIH HHS / CA / CA 105436; United States / NCI NIH HHS / CA / CA 68485; United States / NCI NIH HHS / CA / CA 70856; United States / NIEHS NIH HHS / ES / ES 00267; United States / NIGMS NIH HHS / GM / GM 073407
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


49. Zarineh A, Kozovska ME, Brown WG, Elder DE, Rabkin MS: Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature. J Cutan Pathol; 2008 Oct;35 Suppl 1:83-6
Genetic Alliance. consumer health - Nevus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Smooth muscle hamartoma (SMH) is a rare benign congenital or acquired lesion sometimes associated with Becker's nevus (Becker's melanosis).
  • The superficial portion of the lesion consisted of melanocytes with nevoid morphology.
  • Lesional melanocytes acquired a spindled morphology in the deeper dermis.
  • Unlike a recently reported case of SMH combined with a melanocytic nevus and basal cell carcinoma, the current lesion did not occur in association with a Becker's nevus.
  • [MeSH-minor] Actins / metabolism. Antigens, Neoplasm / metabolism. Calmodulin-Binding Proteins / metabolism. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2008.
  • (PMID = 18544054.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Calmodulin-Binding Proteins; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


50. Wolf EM, Geigl JB, Svrcek M, Vieth M, Langner C: [Hereditary gastric cancer]. Pathologe; 2010 Oct;31(6):423-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This gene encodes the transmembrane protein E-cadherin which plays a central role in cell adhesion and signal transduction.
  • Classified according to Laurén, patients develop multifocal diffuse signet-ring cell carcinoma and, in late stages, linitis plastica.
  • In the foveolar neck region, the site of gastric stem cells, in situ signet-ring cell carcinoma has been identified as a precursor lesion of invasive cancer.
  • Therein, pagetoid spread of tumour cells below the preserved epithelium within the basal membrane represents the characteristic morphology.
  • [MeSH-major] Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Cadherins / genetics. Female. Gastrectomy. Genes, Dominant. Genotype. Germ-Line Mutation. Humans. Male. Mutation, Missense. Neoplasm Staging. Phenotype. Risk Assessment

  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20824432.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins
  •  go-up   go-down


51. Lamovec J, Falconieri G, Salviato T, Pizzolitto S: Basaloid carcinoma of the breast: a review of 9 cases, with delineation of a possible clinicopathologic entity. Ann Diagn Pathol; 2008 Feb;12(1):4-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basaloid carcinoma of the breast (BCB) is an unusual neoplasm composed of basal-type neoplastic cells similar to those found in adenoid cystic carcinoma (ACC), although lacking distinctive features such as a cribriform pattern, a dual neoplastic population (epithelial-myoepithelial/basaloid), and stromal deposits of basement membrane-like material.
  • In this article, we present 9 cases of breast cancer showing overall/predominant basaloid morphology.
  • Microscopically, they featured sheets, nests, and cords of proliferating basaloid tumor cells with ovoid, hyperchromatic nuclei with inconspicuous nucleoli and scant cytoplasm.
  • Tumor cells were positive for wide-spectrum keratins and epithelial membrane antigen (9/9) and high-molecular-weight keratins (7/9).
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Transitional Cell / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Fatal Outcome. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18164408.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


52. Notara M, Daniels JT: Characterisation and functional features of a spontaneously immortalised human corneal epithelial cell line with progenitor-like characteristics. Brain Res Bull; 2010 Feb 15;81(2-3):279-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterisation and functional features of a spontaneously immortalised human corneal epithelial cell line with progenitor-like characteristics.
  • In this study a spontaneously formed corneal epithelial cell line, namely HCE-S, was established and characterised.
  • The cell line was karyotyped and corneal epithelial maker expression of the cell line was assessed by immunostaining and semi-quantitative RT-PCR.
  • The functional response to EGF in terms of cell proliferation, wound healing and cell migration was tested using Alamar Blue, scratch wound and colony dispersion assays, respectively.
  • The cells were maintained in culture for more than 100 divisions and 35 passages suggesting that an immortalised cell line had been established.
  • HCE-S, has maintained an epithelial morphology and has not phenotypicaly changed through passages.
  • HCE-S expressed a battery of characteristic markers of primary corneal epithelial cells including cytokeratin 3 and PAX 6 as well as the basal cell integrins beta1 and alpha9 and the putative corneal stem cell marker ABCG2.
  • HCE-S can be cultured in a simple DMEM and only serum-based media which gives them an advantage against available corneal epithelial cell lines.
  • This fact, along with the often limited availability and variability of primary corneal epithelial cells and the similarities of the cell line with primary cell characteristics suggest that HCE-S could be a useful tool for the study of corneal epithelial cell biology, ocular surface toxicity studies and pharmacological testing.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19699783.001).
  • [ISSN] 1873-2747
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / / G0700219; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Eye Proteins; 0 / Homeodomain Proteins; 0 / Integrins; 0 / Keratin-3; 0 / Neoplasm Proteins; 0 / PAX6 protein; 0 / Paired Box Transcription Factors; 0 / Repressor Proteins; 0 / integrin alpha 9, human; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


53. Kazakov DV, Schaller J, Vanecek T, Kacerovska D, Michal M: Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors. J Cutan Pathol; 2010 Aug;37(8):886-90
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors.
  • The available histopathological material included 24 trichoepitheliomas, 2 large nodular basal cell carcinomas (BCCs), 2 spiradenomas, 1 spiradenocylindroma and 1 trichoblastoma composed of large and small nodules with prominent clear cell differentiation.
  • Whereas one of the two BCCs manifested a conventional morphology, the second neoplasm additionally showed foci with high grade cytological features characterized by marked pleomorphism and numerous mitotic figures.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Basal Cell / genetics. Carcinoma, Skin Appendage / genetics. Facial Neoplasms / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132422.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


54. Gilde K: [Malignant tumors of the skin]. Orv Hetil; 2006 Dec 3;147(48):2321-30
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant tumors of the skin].
  • The most frequent human tumor, the basal cell carcinoma invade slowly progressively destroying all local tissues.
  • Squamous cell carcinoma is less common than its basal cell equivalent but it usually has a more aggressive biological behaviour.
  • [MeSH-major] Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Humans. Keratoacanthoma / diagnosis. Keratoacanthoma / therapy. Melanoma / diagnosis. Melanoma / therapy. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256633.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 25
  •  go-up   go-down


55. Hewes CA, Sullins KE: Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004). J Am Vet Med Assoc; 2006 Nov 15;229(10):1617-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000-2004).
  • OBJECTIVE: To determine outcome for equids with cutaneous neoplasms treated with cisplatin-containing biodegradable beads, alone or in conjunction with debulking.
  • RESULTS: 22 tumors were sarcoids, 6 were fibrosarcomas, 1 was a fibroma, 2 were peripheral nerve sheath tumors, 11 were squamous cell carcinomas, 14 were melanomas (13 gray horses and 1 bay horse), 1 was a lymphosarcoma, 1 was an adenocarcinoma, and 1 was a basal cell tumor.
  • Forty-five (76%) animals underwent conventional or laser debulking of the tumor prior to bead implantation.
  • This included 20 of 22 animals with spindle cell tumors (including 11/13 horses with sarcoids), 6 of 10 animals with squamous cell carcinomas, 13 of 14 animals with melanomas, and 2 of 3 animals with other tumor types.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that implantation of cisplatin-containing biodegradable beads, with or without tumor debulking, may be an effective treatment for equidae with various cutaneous neoplasms.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Equidae. Horse Diseases / drug therapy. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / veterinary. Female. Horses. Laser Therapy / methods. Laser Therapy / veterinary. Male. Melanoma / drug therapy. Melanoma / surgery. Melanoma / veterinary. Retrospective Studies. Sarcoma / drug therapy. Sarcoma / surgery. Sarcoma / veterinary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107319.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


56. Tanioka H, Kawasaki S, Yamasaki K, Ang LP, Koizumi N, Nakamura T, Yokoi N, Komuro A, Inatomi T, Kinoshita S: Establishment of a cultivated human conjunctival epithelium as an alternative tissue source for autologous corneal epithelial transplantation. Invest Ophthalmol Vis Sci; 2006 Sep;47(9):3820-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both the cultivated HCjE cells and the engrafted epithelium manifested five to six layers of stratified squamous epithelium similar in morphology to normal corneal epithelium.
  • The basal cells expressed the putative stem cell markers (ABCG2 and P63) and hemidesmosome and desmosome component proteins.
  • [MeSH-major] Cell Transplantation. Conjunctiva / cytology. Corneal Diseases / surgery. Epithelial Cells / transplantation
  • [MeSH-minor] ATP-Binding Cassette Transporters / metabolism. Animals. Cell Culture Techniques. Epithelium. Epithelium, Corneal / metabolism. Epithelium, Corneal / ultrastructure. Humans. Immunohistochemistry. Keratins / metabolism. Membrane Proteins / metabolism. Mucin-4. Mucins / metabolism. Neoplasm Proteins / metabolism. Rabbits. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936093.001).
  • [ISSN] 0146-0404
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / CKAP4 protein, human; 0 / MUC4 protein, human; 0 / Membrane Proteins; 0 / Mucin-4; 0 / Mucins; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down






Advertisement